Trial Profile
A Phase 1 With Expansion Cohort, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Intravenously Infused IT-141 in Subjects With Recurrent or Refractory Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs IT-141 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Intezyne
- 18 Dec 2020 Status changed from recruiting to discontinued.
- 01 Apr 2017 New trial record
- 30 Mar 2017 Status changed from not yet recruiting to recruiting.